❤ Top 25 Reasons to Love BIEL's Future ❤
1) USA Distribution Partner Could be announced any day—if valued at $300K to $1M, likely to push PPS out of the trips and possibly into COPPER.
2) VA Adoption RecoveryRx now available through VA prosthetics for pain, ortho, and PT—already prescribed at Georgia and Central Texas VA Hospitals.
3) Veterinary Market RecoveryRx-Veterinary could be a goldmine—superior to Assisi Loop with longer battery life and lower cost.
4) Wellness Expansion Off-label use for migraines, menstrual pain, RLS, and more—massive market with minimal regulatory friction.
5) The best technical indicator (Blue Sky Breakout) triggered at .0005, likely to surge the PPS out of the trips.
6) AI-Powered ActiPatch Smartphone-based PEMF therapy.
7) Medtronic Synergy ActiPatch targets the vagus nerve non-surgically.
Strategic Alliance BIEL + Viant + VLMS = Launchpad for partnerships with Vertex (Journavx), Hinge Health, and Medtronic.
9) Technical Indicators & Market Sentiment Golden Cross and Blue Sky Breakout pending. Reddit crowd poised to ignite viral run.
10) Global Expansion South Africa, Taiwan, New Zealand, Bulgaria, etc.
11) Viant & VLMS Billion-Share Stake If disclosed, could trigger a PPS explosion—ROI in days rivaling decades of growth from Amazon, Apple, Microsoft, and NVIDIA.
12) OTC Market Momentum Fed rate cuts historically fuel OTC rallies. Reddit buzz + media frenzy = investor surge + free product advertising.
13) Public Market Leverage Unlocked No IPO or SPAC needed—Viant and VLMS bring FDA-cleared tech, scalable production, and instant market access.
14) Profitability Math $400K quarterly revenue = PPS $0.01. Every $2.5M in annual revenue adds another $0.01 (based on P/E = 100).
15) Equity Partnership Model 1B shares @ $0.0002 = $9.8M profit at $0.01 PPS. That’s a 49x return—comparable to early-stage tech giants.
16) Tax-Efficient Windfall $40M tax-loss carryforward shields early profits—shareholder-friendly upside.
17) Leadership Synergy Sree Koneru (Viant) and Keith Nalepka (VLMS) bring continuity and deep BIEL (BOD level) experience.
18) Strategic Execution Plan Launch ActiPatch base model → ActiPatch+ → Recovery Kits → MSK bundles → Retail via Walgreens/CVS → Medtronic integration.
19) Milestone PPS Targets
$400K quarterly revenue = $0.01
$10M annual profit = $0.04
Full U.S. reimbursement = $0.25–$0.40
Share buyback = $1+
20) Ground-Floor Opportunity PPS at $0.0001–$0.0002. Up to 5% of shares can be acquired instantly—no regulatory hurdles.
21) Equity Windfall Engine Fixed cost basis + FDA expansion + retail adoption = exponential equity value with minimal tax exposure.
22) Arbitrage Playbook Viant & VLMS evolve into hybrid operating-investment entities. PPS-linked upside outpaces traditional margins.
23) BIEL is not just a stock—it's a platform for exponential growth, strategic synergy, and asymmetric upside. The rocket is fueled. Countdown has begun.
24) Tokenized Stock New fundraising channels beyond Wall Street.
25) see 1 - 24!
1) USA Distribution Partner Could be announced any day—if valued at $300K to $1M, likely to push PPS out of the trips and possibly into COPPER.
2) VA Adoption RecoveryRx now available through VA prosthetics for pain, ortho, and PT—already prescribed at Georgia and Central Texas VA Hospitals.
3) Veterinary Market RecoveryRx-Veterinary could be a goldmine—superior to Assisi Loop with longer battery life and lower cost.
4) Wellness Expansion Off-label use for migraines, menstrual pain, RLS, and more—massive market with minimal regulatory friction.
5) The best technical indicator (Blue Sky Breakout) triggered at .0005, likely to surge the PPS out of the trips.
6) AI-Powered ActiPatch Smartphone-based PEMF therapy.
7) Medtronic Synergy ActiPatch targets the vagus nerve non-surgically.
Strategic Alliance BIEL + Viant + VLMS = Launchpad for partnerships with Vertex (Journavx), Hinge Health, and Medtronic. 9) Technical Indicators & Market Sentiment Golden Cross and Blue Sky Breakout pending. Reddit crowd poised to ignite viral run.
10) Global Expansion South Africa, Taiwan, New Zealand, Bulgaria, etc.
11) Viant & VLMS Billion-Share Stake If disclosed, could trigger a PPS explosion—ROI in days rivaling decades of growth from Amazon, Apple, Microsoft, and NVIDIA.
12) OTC Market Momentum Fed rate cuts historically fuel OTC rallies. Reddit buzz + media frenzy = investor surge + free product advertising.
13) Public Market Leverage Unlocked No IPO or SPAC needed—Viant and VLMS bring FDA-cleared tech, scalable production, and instant market access.
14) Profitability Math $400K quarterly revenue = PPS $0.01. Every $2.5M in annual revenue adds another $0.01 (based on P/E = 100).
15) Equity Partnership Model 1B shares @ $0.0002 = $9.8M profit at $0.01 PPS. That’s a 49x return—comparable to early-stage tech giants.
16) Tax-Efficient Windfall $40M tax-loss carryforward shields early profits—shareholder-friendly upside.
17) Leadership Synergy Sree Koneru (Viant) and Keith Nalepka (VLMS) bring continuity and deep BIEL (BOD level) experience.
18) Strategic Execution Plan Launch ActiPatch base model → ActiPatch+ → Recovery Kits → MSK bundles → Retail via Walgreens/CVS → Medtronic integration.
19) Milestone PPS Targets
$400K quarterly revenue = $0.01
$10M annual profit = $0.04
Full U.S. reimbursement = $0.25–$0.40
Share buyback = $1+
20) Ground-Floor Opportunity PPS at $0.0001–$0.0002. Up to 5% of shares can be acquired instantly—no regulatory hurdles.
21) Equity Windfall Engine Fixed cost basis + FDA expansion + retail adoption = exponential equity value with minimal tax exposure.
22) Arbitrage Playbook Viant & VLMS evolve into hybrid operating-investment entities. PPS-linked upside outpaces traditional margins.
23) BIEL is not just a stock—it's a platform for exponential growth, strategic synergy, and asymmetric upside. The rocket is fueled. Countdown has begun.
24) Tokenized Stock New fundraising channels beyond Wall Street.
25) see 1 - 24!
2
